Trial Profile
Phase II trial of erlotinib in advanced pancreatic cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 01 Jun 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 Dec 2008 Basic check conducted, trial sponsor added, last updated 2-12-2008.
- 03 Dec 2008 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.